Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Weleader Biomedical CoROCO:7713 -0.29%42 ROC (Joel Greenblatt) % is 17.40% as of Mar. 2026, which is 0% below its 10-year median of 17.48. GuruFocus rates ROCO:7713 with a GF Score™ of 42/100. The stock has 5 warning signs investors should review. Among 837 Medical Devices & Instruments companies, Weleader Biomedical Co ranks better than 68.1% on this metric.
Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits). He defines ROC (Joel Greenblatt) % as EBIT divided by the total of Property, Plant and Equipment and net working capital. Weleader Biomedical Co's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was 17.40%.
The historical rank and industry rank for Weleader Biomedical Co's ROC (Joel Greenblatt) % or its related term are showing as below:
ROCO:7713'
s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: 16.53 Med: 17.48 Max: 32.95
Current: 18.43
During the past 6 years, Weleader Biomedical Co's highest ROC (Joel Greenblatt) % was 32.95%. The lowest was 16.53%. And the median was 17.48%.
ROCO:7713's ROC (Joel Greenblatt) % is ranked better than 68.1% of 837
companies
in the Medical Devices & Instruments industry
Industry Median: 4.48
vs ROCO:7713: 18.43
Weleader Biomedical Co's 5-Year average Growth Rate of ROC (Joel Greenblatt) % was -7.00% per year.
Weleader Biomedical Co (ROCO:7713) ROC (Joel Greenblatt) % Explanation
The way Joel Greenblatt defines Return on Capital is a more accurate measure of how efficiently the company generates returns onthe capital actually invested in the business. EBIT is used instead of net income because the tax and interest payment may be affected by factors other than the core business operation. Intangible assets are not included in the calculation because they don't need to be replaced.
Weleader Biomedical Co ROC (Joel Greenblatt) % Related Terms
Weleader Biomedical Co ROC (Joel Greenblatt) % Historical Data
* Premium members only.
The historical data trend for Weleader Biomedical Co's ROC (Joel Greenblatt) % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Weleader Biomedical Co ROC (Joel Greenblatt) % Chart
ROCO:7713 vs ABT, SYK, MDT: ROC (Joel Greenblatt) % Comparison
For the Medical Devices subindustry, Weleader Biomedical Co's ROC (Joel Greenblatt) %, along with its competitors' market caps and ROC (Joel Greenblatt) % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Weleader Biomedical Co ROC (Joel Greenblatt) % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Weleader Biomedical Co's ROC (Joel Greenblatt) % distribution charts can be found below:
* The bar in red indicates where Weleader Biomedical Co's ROC (Joel Greenblatt) % falls into.
Weleader Biomedical Co ROC (Joel Greenblatt) % Calculation
Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits) . He defines Return on Capital as follows:
EBIT stands for Earnings Before Interest and Taxes.
Fixed Assets are also known as non-current assets. They include the Property, Plant and Equipment that the firm needs in its operation.
GuruFocus calculates net working capital as: (Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Deferred Revenue + Other Current Liabilities). We're trying to account for OPERATING assets and liabilities (part of daily business) when calculating working capital. Cash and marketable securities are considered NON-OPERATING assets and are not included in calculation. We will also back out all interest bearing debt, short term debt and the portion of long term debt that is due in the current period from the current liabilities. This debt will be considered when computing cost of capital and it would be inappropriate to count it twice.
Note:
The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a ROC (Joel Greenblatt) % of 17.40% mean?
Weleader Biomedical Co (ROCO:7713) has a ROC (Joel Greenblatt) % of 17.40% as of Mar. 2026. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on Weleader Biomedical Co and its competitors. This is near median its historical median of 17.48. Over the past decade, Weleader Biomedical Co's ROC (Joel Greenblatt) % has ranged from 16.53 to 32.95. According to the industry distribution chart, Weleader Biomedical Co ranks #267 out of 837 companies in the Medical Devices & Instruments industry, placing it in the top 31.9%.
Is Weleader Biomedical Co's ROC (Joel Greenblatt) % too high?
Weleader Biomedical Co's current ROC (Joel Greenblatt) % of 17.40% is near median its 10-year median of 17.48. Over the past 10 years, this metric has ranged from a low of 16.53 to a high of 32.95. The Medical Devices & Instruments industry median ROC (Joel Greenblatt) % is 4.48. Weleader Biomedical Co's value of 17.40% is 288.4% above this industry median. Based on the distribution chart, Weleader Biomedical Co ranks #267 out of 837 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Weleader Biomedical Co has a GF Score™ of 42/100, reflecting its overall financial health beyond just this single metric.
How does Weleader Biomedical Co's ROC (Joel Greenblatt) % compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Weleader Biomedical Co ranks #267 out of 837 companies for ROC (Joel Greenblatt) %. This puts Weleader Biomedical Co in the upper half of its industry. The industry median ROC (Joel Greenblatt) % is 4.48. Weleader Biomedical Co's value of 17.40% is 288.4% above this benchmark. Historically, Weleader Biomedical Co's own ROC (Joel Greenblatt) % has ranged from 16.53 to 32.95 over the past decade. While the company's 10-year median is 17.48 vs. the industry median of 4.48, Weleader Biomedical Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROC (Joel Greenblatt) % for a Medical Devices & Instruments company?
The median ROC (Joel Greenblatt) % among Medical Devices & Instruments companies is 4.48, based on 837 companies in the industry. Companies in the top quartile (top 25%) have a ROC (Joel Greenblatt) % significantly above this median, while those in the bottom quartile fall well below. However, ROC (Joel Greenblatt) % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Weleader Biomedical Co's current ROC (Joel Greenblatt) % of 17.40% is 288.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROC (Joel Greenblatt) % mean?
A high ROC (Joel Greenblatt) % can signal that a stock is expensive relative to its fundamentals. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on Weleader Biomedical Co and its competitors. For the Medical Devices & Instruments industry, the median ROC (Joel Greenblatt) % is 4.48 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Weleader Biomedical Co's current ROC (Joel Greenblatt) % is 17.40%, which is near median its own 10-year median of 17.48. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Weleader Biomedical Co stock overvalued right now?
Weleader Biomedical Co (ROCO:7713) has a current ROC (Joel Greenblatt) % of 17.40%. The current ROC (Joel Greenblatt) % is 17.40%, which is near median its 10-year median of 17.48 and 288.4% above the Medical Devices & Instruments industry median of 4.48. Weleader Biomedical Co's overall GF Score™ is 42/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROC (Joel Greenblatt) % calculated?
ROC (Joel Greenblatt) % is calculated from a company's financial statements. For Weleader Biomedical Co (ROCO:7713), the current ROC (Joel Greenblatt) % is 17.40% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Weleader Biomedical Co Ltd is mainly engages in the sales of medical testing reagents and medical devices; and the leasing of testing instruments. The reportable segments of the Group are: The Company, which includes sale of testing reagents, and provision of testing instruments and services; and Health Leader, which includes sale of dietary supplements and testing reagents, and provision of information and professional services. It derives majority revenue from the Company segment. Geographically, the company operates and generates revenue from Taiwan.
42GF Score
Get the complete analysis for ROCO:7713
ROC (Joel Greenblatt) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:7713 has been successfully added to your 
